In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
News|Articles|March 31, 2026
March Roundup of FDA Approvals in Oncology: 4 Decisions to Know
Author(s)Kristi Rosa
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in March 2026 spanning tumor types.
Advertisement
Advertisement
Below is your guide to all the oncologic options that were approved, rejected, or withdrawn by the FDA in March 2026. The regulatory roundup provides everything you need to know, right at your fingertips—all the topline data that supported the decisions and expert insights detailing clinical practice implications.
Related to this article
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
A rituximab biosimilar has been approved by the FDA.
Antibodies directed against TNFR2, a regulator in the tumor microenvironment that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
PD-L1 IHC 22C3 pharmDx gained EU approval as a companion diagnostic for pembrolizumab in platinum-resistant epithelial ovarian cancer.
The CLDN18.2/CD47 bispecific antibody spevatamig has received FDA fast track designation for advanced and metastatic biliary tract carcinoma.
Advertisement
Advertisement